Matinas BioPharma Holdings, Inc. (NYSE:MTNB) reached 26.73% versus a 1-year low price of $1.01. The stock was last seen 4.07% higher, reaching at $1.28 on 10/17/2017. At recent session, the prices were hovering between $1.21 and $1.28. This company shares are 499.22% off its target price of $7.67 and the current market capitalization stands at $122.25M. The recent change has given its price a -2.79% deficit over SMA 50 and -67.92% deficit over its 52-week high. The stock witnessed -0.78% declines, -11.72% declines and -55.24% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found MTNB’s volatility during a week at 6.79% and during a month it has been found around 5.36%.Matinas BioPharma Holdings, Inc. (MTNB) Top Holders
Institutional investors currently hold around $13 million or 10.7% in MTNB stock. Look at its top three institutional owners. Vanguard Group Inc owns $3.01 million in Matinas BioPharma Holdings, Inc., which represents roughly 2.46% of the company’s market cap and approximately 23.15% of the institutional ownership. Similar statistics are true for the second largest owner, Blackrock Inc., which owns 2,396,440 shares of the stock are valued at $2.95 million. The third largest holder is Ifp Advisors, Inc, which currently holds $861 thousand worth of this stock and that ownership represents nearly 0.7% of its market capitalization.Matinas BioPharma Holdings, Inc. 13F Filings
At the end of June reporting period, 38 institutional holders increased their position in Matinas BioPharma Holdings, Inc. (NYSE:MTNB) by some 8,901,012 shares, 11 decreased positions by 787,519 and 3 held positions by 937,979. That puts total institutional holdings at 10,626,510 shares, according to SEC filings. The stock grabbed 33 new institutional investments totaling 8,559,534 shares while 7 institutional investors sold out their entire positions totaling 251,330 shares.Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Insider Trades
Multiple company employees have indulged in significant insider trading. Matinas BioPharma Holdings, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Chief Scientific Officer Mannino Raphael J has acquired 5,000 shares of Matinas BioPharma Holdings, Inc. (MTNB) in trading session dated Sep. 11, 2017. These shares are worth $7,050 and were traded at $1.41 each. The SEC filing shows that Stern Adam K performed a purchase of 100,000 shares. The Director added these shares by way of transaction on Sep. 08, 2017. The company’s shares were assimilated at $1.38 per share worth to an investment of some $138,000 on account of Stern Adam K.
CEO, Rongen Roelof, purchased 5,000 common shares of Matinas BioPharma Holdings, Inc. (MTNB) in the open market. In a transaction dated Sep. 08, 2017, the shares were bought at an average price of $1.36, giving away a sum of $6,800. After this purchase, 3,539,416 common shares of MTNB are directly owned by the insider, with total stake valued at $4,530,452.
In the transaction dated Sep. 07, 2017, the great number of shares acquired came courtesy the Director; Scibetta James S added a total of 5,000 shares at an average price of $1.29, amounting to approximately $6,450. The insider now directly owns 418,309 shares worth $535,436.Matinas BioPharma Holdings, Inc. (MTNB) Analyst Guide
Several analysts have released their opinion on Matinas BioPharma Holdings, Inc. (NYSE:MTNB), with 3 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1 average brokerage recommendation.